MVRTAVLILLLVRFSEPKHKLEQLRNSGAAAEEEEYMPMEMNNSTNSSNNSLALTSPYKT
FEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNYFLFSLACADLIIGVFSMNLYTLYTV
IGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKRTTKMAGMMIAAAWVL
SFILWAPAILFWQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKS
RIKKDKKEPVANQDPVSPSLVQGRIVKPNNNNMPSSDDGLEHNKIRDPVTENCVQGEEKESSNDS
TSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSG
QNGDEKQNIVARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPC
IPNTVWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR (SEQ ID NO:19)

FIG. 1

MKFLVNVALVFMVVYISYIYADYKDDDDKMGQPGNGSAFLLAPNRSHAPDHDVTQQRDEV
WVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILM
KMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVS
GLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEA
KRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFI
VNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSS
NGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLLEEEEYMPM
E (SEQ ID NO:20)

FIG. 2

MKTIIALSYIFCLVFAMAILPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQL
LDQAGNLSSSPSALGLPVRSPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWI
ILAHKRMRTVTNYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIY
SMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPE
GPKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKMMIIV
VMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLNKRFRAGFKR
AFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADTTRSSRKKRATPRDP
SFNGCSRRNSKSASATSSFISSPYTSVDEYSQPELAPEDPEDAAKHKLEQLRNSG (SEQ ID
NO:21)

FIG. 3

MKFLVNVALVFMVVYISYIYADYKDDDDKMNTSAPPAVSPNITVLAPGKGPWQVAFIGIT
TGLLSLATVTGNLLVLISFKVNTELKTVNNYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTL
ACDLWLALDYVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAI
LFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQ
GSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSS
EGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFS
LVKEKKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYALC
NKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQCEEEEYMPME (SEQ ID NO:22)

FIG. 4

MKTIIALSYIFCLVFAMTLHSNSTTSPLFPNISSSWVHSPSEAGLPLGTVTQLGSYNISQ
ETGNFSSNDTSSDPLGGHTIWQVVFIAFLTGFLALVTIIGNILVIVAFKVNKQLKTVNNYFLLSL
ACADLIIGVISMNLFTTYIIMNRWALGNLACDLWLSIDYVASNASVMNLLVISFDRYFSITRPLT
YRAKRTTKRRGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAEAENFVHPTGSSRSCSSYELQQQGVKRSSR
RKYGRCHFWFTTKSWKPSAEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSETRAIYSIVLK
LPGHSSILNSTKLPSSDNLQVSNEDLGTVDVERNAHKLQAQKSMGDGDNCQKDFTKLPIQLESAV
DTGKTSDTNSSADKTTATLPLSFKEATLAKRFALKTRSQITKRKRMSLIKEKKAAQTLSAILLAF
IITWTPYNIMVLVNTFCDSCIPKTYWNLGYWLCYINSTVNPVCYALCNKTFRTTFKTLLLCQCDK
RKRRKQQYQQRQSVIFHKRVPEQALQPELAPEDPEDAAHHHHHHHH (SEQ ID NO:23)

FIG. 5

SEC CHROMATOGRAMS



FIG. 6

COX-1 ALIS with Test Libraries

NSAID LIGAND MIX RECOVERY, COX-1 METHODS DEVELOPMENT 10-19-00



FIG. 7

Example COX-1 Ligand Identitied by ALIS

NGL-177-A-1128-A-2

$C_{31}H_{31}N_3O_5$

MW = 525.6

MASS = 525.23



FIG. 8


LIGAND - COMPETITOR
LIGAND + COMPETITOR
MECLOFENAMATE
COX-1 LIGAND COMPETITION EXPERIMENTS 11-16-00,
SUBLIBRARY ± 25μM MECLOFENAMATE
COX-1 + 25 μM MECLOFENAMATE
NGL-159-A-1110-A-1
NGL-159-A-1118-A-2
NGL-159-A-1118-A-3
NGL-161-A-1123-A-6
NGL-161-A-1150-A-2
NGL-161-A-1154-A-1
NGL-169-A-1151-A-4
NGL-169-A-1151-A-8
NGL-173-A-1157-A-3
NGL-175-A-1127-A-1
NGL-177-A-1128-A-1
NGL-177-A-1128-A-2
NGL-178-A-1114-A-3
NGL-192-A-1132-A-1
NGL-194-A-1139-A-2
64.0
24.7
27.7
19.8
47.1
49.6
28.9
30.0
35.9
52.1
45.9
50.3
46.2
48.6
0.0
100.0
200.0
300.0
400.0
500.0
600.0
MS RESPONSE

FIG. 9



FIG. 10